Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TPMT | P51580 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | RHOA | P61586 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL175786 | 0.90 | SNCA (0.67) | SNCACYP3A4ALDH1A1TSHRHSD17B10 | |
| SCHEMBL461801 | 0.85 | SNCA (0.61) | SNCACYP3A4ALDH1A1TSHRHSD17B10 | |
| SCHEMBL17386391 | 0.85 | SNCA (0.61) | SNCACYP3A4ALDH1A1TSHRHSD17B10 | |
| SCHEMBL31182 | 0.83 | SNCA (0.59) | SNCACYP3A4ALDH1A1TSHRHSD17B10 | |
| SCHEMBL5675836 | 0.83 | SNCA (0.59) | SNCACYP3A4ALDH1A1TSHRHSD17B10 | |
| SCHEMBL175787 | 0.83 | SNCA (0.59) | SNCACYP3A4ALDH1A1TSHRHSD17B10 | |
| SCHEMBL2705494 | 0.81 | SNCA (0.58) | SNCACYP3A4ALDH1A1TSHRHSD17B10 | |
| Hydrochloric Acid SCHEMBL9285006 | 0.81 | SNCA (0.58) | SNCACYP3A4ALDH1A1TSHRHSD17B10 | |
| SCHEMBL9270334 | 0.81 | SNCA (0.58) | SNCACYP3A4ALDH1A1TSHRHSD17B10 | |
| SCHEMBL1882104 | 0.81 | SNCA (0.58) | SNCACYP3A4ALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004611-A1 | PROCESS FOR PREPARING RETINOID COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2008-12-24 | — | — | EP | claimed |
| WO-2007113122-A1 | PROCESS FOR PREPARING RETINOID COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-11 | — | — | WO | claimed |
| US-20070232810-A1 | Process for preparing retinoid compounds | ROCHE PALO ALTO LLC | 2007-10-04 | — | — | US | claimed |
| EP-1390340-B1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INST TECHNOLOGY (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9067955-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon—carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-06-30 | — | — | US | disclosed |
| US-8034960-B2 | Process for the synthesis C-2, C-3 substituted N-alkylated indoles useful as cPLA2 inhibitors | PFIZER INC. (US) | 2011-10-11 | — | — | US | disclosed |
| EP-1778629-B1 | PROCESS FOR THE SYNTHESIS C-2, C-3 SUBSTITUTED N-ALKYLATED INDOLES USEFUL AS CPLA2 INHIBITORS | WYETH LLC (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110054189-A1 | Process For The Synthesis C-2, C-3 Substituted N-Alkylated Indoles Useful As CPLA2 Inhibitors | WYETH LLC | 2011-03-03 | — | — | US | disclosed |
| US-7842837-B2 | Process for the synthesis of C-2, C-3 substituted N-alkylated indoles useful as cPLA2 inhibitors | WYETH LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090306428-A1 | Process for the Synthesis of C-2, C-3 Substituted N-Alkylated Indoles Useful as cPLA2 Inhibitors | WYETH LLC | 2009-12-10 | — | — | US | disclosed |
| US-7582772-B2 | Process for the synthesis C-2, C-3 substituted N-alkylated indoles useful as CPLA2 inhibitors | WYETH (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1390340-A1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20040019216-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-29 | — | — | US | disclosed |
| EP-1212316-B1 | BENZOPYRANS AND BENZOTHIOPYRANS AS RAR SELECTIVE RETINOID AGONISTS | HOFFMANN LA ROCHE (CH) | 2003-10-15 | — | — | EP | disclosed |
| US-20030065187-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-04-03 | — | — | US | disclosed |
| US-6479670-B1 | Selective retinoid acid receptor agonists | HOFFMANN-LA ROCHE INC. | 2002-11-12 | — | — | US | disclosed |
| WO-2002085838-A1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-10-31 | — | — | WO | disclosed |
| EP-1212316-A2 | BENZOPYRANS AND BENZOTHIOPYRANS AS RAR SELECTIVE RETINOID AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001014360-A2 | BENZOPYRANS AND BENZOTHIOPYRANS AS RAR SELECTIVE RETINOID AGONISTS | F. HOFFMAN-LA ROCHE AG (CH) | 2001-03-01 | — | — | WO | disclosed |
| US-4644025-A | Lens materials of high refractive indexes | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1987-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054189-A1 | Process For The Synthesis C-2, C-3 Substituted N-Alkylated Indoles Useful As CPLA2 Inhibitors | PLA2G4A, PLA2G4B, PLA2G1B | SNCA 3573/4885CYP3A4 607/4885ALDH1A1 2632/4885 |
| US-20090306428-A1 | Process for the Synthesis of C-2, C-3 Substituted N-Alkylated Indoles Useful as cPLA2 Inhibitors | PLA2G4A, PLA2G12A, PLA2R1 | SNCA 4043/4885CYP3A4 353/4885ALDH1A1 1722/4885 |
| US-20030065187-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | ADH5, CBR3, ALDH3A1 | SNCA 1224/4885CYP3A4 184/4885ALDH1A1 26/4885 |
| US-20040019216-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | ADH5, CBR3, ALDH3A1 | SNCA 1224/4885CYP3A4 184/4885ALDH1A1 26/4885 |
| US-20070232810-A1 | Process for preparing retinoid compounds | RARB, RARG, RARA | SNCA 4568/4885CYP3A4 252/4885ALDH1A1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.